Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

With very few adjuvants currently being used in marketed human vaccines, a critical need
exists for novel immunopotentiators and delivery vehicles capable of eliciting humoral …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

Aminoacyl transfer RNA (tRNA) synthetases (aaRSs) are attractive drug targets, and we
present class I and II aaRSs as previously unrecognized targets for adenosine 5 …

Malaria caused by Plasmodium falciparum remains a major public health threat, especially
among children and pregnant women in Africa. An effective malaria vaccine would be a …

Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

The malaria vaccine Combination B comprises recombinant Plasmodium falciparum ring-
infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) …

The development of effective malaria vaccines and immune biomarkers of malaria is a high
priority for malaria control and elimination. Ags expressed by merozoites of Plasmodium …

Rolling back malaria is possible. Tools are available but they are not used. Several
countries deploy, as their national malaria control treatment policy, drugs that are no longer …

Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1
million deaths and an estimated 243 million clinical cases annually. Several candidate …